| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-06-30 |
|---|---|---|---|---|
| License revenue | 0 | 0 | - | - |
| Research and development | 22,950 | 27,610 | 27,247 | 48,386 |
| General and administrative | 10,784 | 8,448 | 10,580 | 16,762 |
| Restructuring | 0 | 0 | 7,796 | - |
| Total operating expenses | 33,734 | 36,058 | 45,623 | 65,148 |
| Loss from operations | -33,734 | -36,058 | -45,623 | -65,148 |
| Investment and other income, net | 7,043 | 9,184 | -2,656 | -22,863 |
| Net loss before income taxes | -26,691 | -26,874 | -48,279 | -88,011 |
| Income tax expense (benefit) | 0 | 0 | - | 266 |
| Net loss | -26,691 | -26,874 | -48,279 | -88,277 |
| Net loss attributable to noncontrolling interests | 0 | 0 | - | - |
| Net loss attributable to zentalis | -26,691 | -26,874 | -48,279 | -88,277 |
| Net loss per common share outstanding, basic (in dollars per share) | -0.37 | -0.37 | -0.67 | -1.24 |
| Net loss per common share outstanding, diluted (in dollars per share) | -0.37 | -0.37 | -0.67 | -1.24 |
| Weighted average number of common shares outstanding, basic (in shares) | 72,139,000 | 71,992,000 | 71,678,000 | 71,040,000 |
| Weighted average number of common shares outstanding, diluted (in shares) | 72,139,000 | 71,992,000 | 71,678,000 | 71,040,000 |
Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL)